

**Ref: BHL/ STEX 46/ 2025-26**

**Date: October 17, 2025**

<b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001  <b>Scrip Code: 539872</b>	<b>National Stock Exchange of India Limited</b> 5 <sup>th</sup> Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051  <b>Symbol: BAJAJHCARE</b>
--	---

**Sub: Press Release for the Quarter ended September 30, 2025**

Dear Sir/Madam,

Please find enclosed herewith Press Release on financial results of the Company for the quarter ended September 30, 2025.

Kindly take the same on record.

Thanking you.

Yours faithfully,

**For and on behalf of Board of Directors  
of Bajaj Healthcare Limited**

**Monica Tanwar  
Company Secretary & Compliance Officer**

***Encl: As above***



## Investor Release

### Bajaj Healthcare Limited reports Q2 & H1 FY26 results

**(Strong margin expansion drives profitability)**

**Mumbai, 17<sup>th</sup> Oct 2025:** Bajaj Healthcare Limited, one of the leading manufacturers of APIs, Intermediates and Formulations, announced its Un-Audited Financial Results for the quarter and half year ended 30<sup>th</sup> September 2025.

#### Key Financial Highlights

Particulars (Rs. Mn)	Q2 FY26	Q2 FY25	Y-o-Y	H1 FY26	H1 FY25	Y-o-Y
Revenue from Operations	1,479.1	1,330.9	<b>11.1%</b>	2,967.5	2,653.4	<b>11.8%</b>
EBITDA	286.0	271.3	<b>5.4%</b>	539.9	524.9	<b>2.9%</b>
EBITDA Margin (%)	19.1%	20.0%		18.0%	19.5%	
PAT from Cont. Operations	124.5	83.4	<b>49.2%</b>	246.2	163.7	<b>50.4%</b>
PAT Margin (Cont. Operations)	8.3%	6.1%		8.2%	6.1%	
Profit for the period	111.1	94.6	<b>17.4%</b>	229.4	166.0	<b>38.2%</b>
Profit for the period(%)	7.4%	7.0%		7.7%	6.2%	

#### Revenue Breakup

Particulars (Rs. Mn)	Q2 FY26	Q2 FY25	Y-o-Y	H1 FY26	H1 FY25	Y-o-Y
API (Domestic)	762.8	806.3	<b>-5.4%</b>	1,488.7	1,648.5	<b>-9.7%</b>
API (Exports)	487.3	292.0	<b>66.9%</b>	1,009.2	601.9	<b>67.7%</b>
Formulations	229.1	232.6	<b>-1.5%</b>	469.6	403.0	<b>16.5%</b>

#### Key Business Highlights

- ✓ Received SEC-CDSCO recommendation to initiate Phase III clinical trials for Suvorexant Tablets, becoming the first company in India to secure this nod for the insomnia molecule. This reflects our long-standing experience and proven execution capabilities in drug development and clinical research.
- ✓ Secured DCGI approval to conduct phase III clinical trials for Cenobamate Tablets, a novel anti-epileptic molecule; the clinical trials are currently underway. This marks an important step in strengthening our presence in CNS space where we develop innovative and high-potential molecules.



- ✓ Filed two new CEPs during the quarter, taking cumulative filings to ten (seven approved, three under review); two additional CEPs currently in progress, further strengthening our position in regulated EU and UK markets.
- ✓ During this quarter, we have filed few DMFs. Overall, till date we have filed 60 DMFs in various countries. We will continue to strengthen our regulatory filings.

**Commenting on the Results, Mr. Anil Jain – Managing Director said,**

*“Our Q2 FY26 performance underscores the resilience of our operations and the strength of our strategic execution, despite ongoing tariff tensions and global uncertainty. Revenue from operations grew 11% year-on-year. Sequentially, gross margin expanded by 462 basis points to 50.8%, while EBITDA margin improved by 217 basis points to 19.1%, resulting in profit from continuing operations growing by a strong 49% year-on-year and reaffirming our focus on sustainable earnings growth.*

*This improvement in margins and profitability was driven by strong growth in exports (up 67% year-on-year) and formulations during the quarter. While pricing pressure persists in the domestic API segment, we continue to pursue opportunities in high-margin products to support long-term margin stability.*

*On the regulatory front, we continue to strengthen our global compliance framework and advance product registrations across key geographies. Our focus remains on expanding our presence in regulated markets and aligning our pipeline with high-value therapeutic areas that offer long-term growth potential.*



*With a strong foundation, enhanced regulatory preparedness, and continued investment in R&D, we are well-positioned to sustain growth momentum and drive expansion across our API and formulations businesses. We have also strengthened our key management people with industry leaders across key divisions, enabling us to achieve sustainable and scalable growth. We remain committed to creating long-term value for the healthcare ecosystem and our stakeholders.”*

**About Bajaj Healthcare Ltd:**

Bajaj Healthcare Limited a leading Manufacturer of APIs, Intermediates and Formulations. Established in the year 1993. It specializes in manufacturing of intermediates, API, formulations & Nutraceuticals. The Company has state-of-art manufacturing facilities of APIs, intermediates and formulations. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Middle East and South America.



## Contact Details

Bajaj Healthcare Ltd	Investor Relations: MUFG Intime India Pvt. Ltd.
	
CIN: L99999MH1993PLC072892	Name: Ms. Prachi Ambre/ Mr. Irfan Raeen
Name: Mr. Anil Jain, MD	Email: <a href="mailto:prachi.ambre@in.mpms.mufg.com">prachi.ambre@in.mpms.mufg.com</a> / <a href="mailto:irfan.raeen@in.mpms.mufg.com">irfan.raeen@in.mpms.mufg.com</a>
Email: <a href="mailto:investors@bajajhealth.com">investors@bajajhealth.com</a>	Meeting Request Link – <a href="#">Click Here</a>

## Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.